Clinical trials in Marseille – page 11

1 490 clinical trials in Marseille, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Marseille at a glance

1 490

clinical trials

Research sites7

Quick filters

1 490 trials in Marseille

Open in trial search

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and sigvotatug vedotin in patients with advanced solid tumors

InvestigationalNo placebo

A study of PF-08634404 and sigvotatug vedotin in patients with advanced solid tumors

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Sigvotatug vedotin
Sponsor:Pfizer Inc.

Contact Research Centre

Lung neoplasm malignant+2

Recruiting

A study to evaluate the effectiveness of tarlatamab in patients with extensive-stage small cell lung cancer that has progressed after prior treatment and who have limited health status

InvestigationalNo placebo

A study to evaluate the effectiveness of tarlatamab in patients with extensive-stage small cell lung cancer that has progressed after prior treatment and who have limited health status

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Tarlatamab
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

Congenital myopathy

Recruiting

A study to evaluate the safety and effectiveness of surlorian in adults with RYR1-related myopathy

Investigational

A study to evaluate the safety and effectiveness of surlorian in adults with RYR1-related myopathy

Investigational

France

Participants:18–64 years · 65+ years
Sponsor:Rycarma Therapeutics Inc.

Contact Research Centre

Acute lymphocytic leukaemia

Recruiting

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Asparaginase
Sponsor:Amgen Inc.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Non-small cell lung cancer metastatic

Recruiting

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo

A study of rilvegostomig and ramucirumab in patients with advanced or metastatic non-small cell lung cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Ramucirumab
Sponsor:AstraZeneca AB

Contact Research Centre

Bile duct cancer

Recruiting

A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

Registered drugNo placebo

A study of rilvegostomig, cisplatin, and gemcitabine compared to durvalumab and a drug combination for adults with advanced biliary tract cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cisplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Breast cancer

Recruiting

Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

Registered drug

Study of inavolisib, ribociclib, and fulvestrant for patients with advanced hormone-receptor-positive, HER2-negative breast cancer.

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Fulvestrant
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Bronchiectasis

Recruiting

A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

Investigational

A study to evaluate the safety and effectiveness of AZD0292 in people aged 12 years and older with bronchiectasis and chronic Pseudomonas aeruginosa infection

Investigational

France

Participants:18–64 years · 65+ years
Substances:AZD0292
Sponsor:AstraZeneca AB

Contact Research Centre

Neoplasm malignant

Recruiting

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo

A study of YL201 and atezolizumab for patients with advanced solid tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Medilink Therapeutics (Suzhou) Co. Ltd.

Contact Research Centre

Interstitial lung disease+1

Recruiting

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease

Investigational

France

Participants:18–64 years · 65+ years
Substances:Treprostinil
Sponsor:Liquidia Technologies Inc.

Contact Research Centre

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Marseille

What the registry says about research in the country

01 Oncology Research

Studies focusing on innovative treatments for head and neck squamous cell carcinoma, examining novel therapies and combinations with radiotherapy. Research includes investigations into endometrial cancer and bladder cancer treatments.

Advanced tumor treatments
Immunotherapy combinations
Targeted therapies

Particular emphasis on combining immunotherapy with conventional treatments for improved patient outcomes.

02 Cardiovascular and Metabolic Disorders

Innovative research addressing heart failure prevention and treatment of acute myocardial infarction. Studies include new approaches for managing hypertriglyceridemia and chronic kidney disease.

Preventive cardiology
Emergency cardiac care
Metabolic conditions

Focus on developing novel therapeutic approaches and improving patient outcomes in cardiovascular health.

03 Neurological Conditions

Clinical investigations into multiple sclerosis treatment strategies and management of essential tremor. Research includes innovative approaches for Dravet Syndrome and neurological disorders.

Movement disorders
Autoimmune conditions
Seizure management

Emphasis on developing targeted therapies for various neurological conditions affecting both adults and children.

Back to France All countries